drugset

Drugs / N-acetylcisteine

Follow last change Feb 2022 re-read 2 minutes ago

N-acetylcisteine

also known as N-acetilcysteine

Other / unclassified

Developed for: polycystic ovary syndrome
Investigated by: Grupo CINUSA (Centros de Investigación en Nutrición y Salud S.L.) · Margan Biotech

Trials 1 · a red edge is where a trial was stopped

today NCT05340634 · Ph 4

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT05340634	Apr 2020 → Feb 2022	polycystic ovary syndrome	Margan Biotech	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT01594489 Comparator	Jan 2009 → Sep 2012	acute kidney injury	Ospedale Misericordia e Dolce	Completed	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	N-acetylcisteine	“200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 mg vitamin B6” NCT05340634 ↗ 1 NCT01594489 ↗
Known as	N-acetilcysteine	“N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI” NCT01594489 ↗
Modality	Other / unclassified	“as a dietary supplement” NCT05340634 ↗
Route	Intravenous	“N-acetilcysteine: intravenous bolus” NCT01594489 ↗